tirzepatide cancer BREAKING NEWS 🚨 A new study from the University of Michigan found that SHRINKS BREAST TUMORS IN MICE. For women 40–55, this matters. Weight gain and breast cancer risk both GLP-1s and Cancer: Emerging Research

The most common side effects of the drugs are nausea, diarrhoea, constipation and dehydration, although the US Food and Drug Administration last week revealed it was evaluating the risk of more serious side effects including hair loss and suicidal ideation

D.JacquotJ.-P

Are used during initial loading phases or in patients with higher metabolic demand (active weight loss programs, metabolic dysfunction-associated steatotic liver disease)

Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective

Incidence of hypoglycemia measured by continuous glucose monitor and number of hypoglycemic events were decreased in the subjects treated with exendin-(9-39)

In 1983 Mojsov sketched out her hypothesis on the back of the sequence Bell and his colleagues had worked out for the human glucagon gene